ASCO GI 2023 Conference Coverage


 

ASCO GI 2023 Survival Analysis of the Phase II Randomized DEEPER Trial by JACCRO: m-FOLFOXIRI + Cetuximab vs. m-FOLFOXIRI + Bevacizumab as Initial Treatment for Unresectable RAS & BRAF Wild-Type mCRC

309 views
January 20, 2023
Comments 0
Login to view comments. Click here to Login